Lupin announced the launch of Potassium Chloride (KCI) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin's Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software
Solution, LLC's Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis
of hypokalemia with or without metabolic alka losis in patients for whom dietary management with potassium-rich
foods or diuretic dose reduction is insufficient.
Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately USD 90 million in the U.S.
(IQVIA MAT September 2019).